Drug Profile
Research programme: adenosine A3 selective antagonists - Domain Therapeutics
Alternative Names: DT 0522; DT 0738; FP 0522Latest Information Update: 15 Jan 2014
Price :
$50
*
At a glance
- Originator Faust Pharmaceuticals
- Developer Domain Therapeutics
- Class 3-ring heterocyclic compounds; Pyrroles; Quinoxalines; Small molecules
- Mechanism of Action Adenosine A3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Cancer; Chronic obstructive pulmonary disease; Glaucoma
Most Recent Events
- 26 Aug 2010 Pharmacodynamics data from a preclinical trial in Glaucoma presented at the 240th American Chemical Society National Meeting (2340th-ACS-2010)
- 20 Nov 2009 Domain Therapeutics' selective adenosine A3 antagonists programme for glaucoma is available for partnering (http://www.domaintherapeutics.com)